Close antiplatelet therapy monitoring and adjustment based upon thrombelastography may reduce late-onset bleeding in HeartMate II ecipients

Interactive Cardiovascular and Thoracic Surgery

Volumn 18, Issue 4, 2014, Pages 457-464

  Karimi, Ashkan ^a   Beaver, Thomas M ^a   Hess, Philip J ^a   Martin, Tomas D ^a   Staples, Edward D ^a   Schofield, Richard S ^a   Hill, James A ^a   Aranda, Juan M ^a   Klodell, Charles T ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Bleeding; HeartMate II; Stroke; Thrombelastography; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE; EPTIFIBATIDE; HEPARIN; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ADULT; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG DOSE ESCALATION; EARLY ONSET BLEEDING; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; KAPLAN MEIER METHOD; LATE ONSET BLEEDING; LEFT VENTRICULAR ASSIST DEVICE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SUSPECTED PUMP THROMBOSIS; THROMBOELASTOGRAPH; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; UNIVARIATE ANALYSIS; AGE; AGED; CHI SQUARE DISTRIBUTION; DRUG MONITORING; HEART ASSIST DEVICE; HEMORRHAGE; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; RETROSPECTIVE STUDY; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTICOAGULANTS; CHI-SQUARE DISTRIBUTION; DRUG MONITORING; FEMALE; HEART-ASSIST DEVICES; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBELASTOGRAPHY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896945570     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1093/icvts/ivt546     Document Type: Article

References (17)

1. Garbade J, Bittner HB, Barten MJ, Mohr FW. Current trends in implantable left ventricular assist devices. Cardiol Res Pract 2011;2011:290561.
2. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D et al. Advanced heart failure treated with continuousflow left ventricular assist device. N Engl J Med 2009;361:2241-51.
3. Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007;357:885-96.
4. Pagani FD, Miller LW, Russell SD, Aaronson KD, John R, Boyle AJ et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 2009;54:312-21.
5. Boyle AJ, Russell SD, Teuteberg JJ, Slaughter MS, Moazami N, Pagani FD et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant 2009;28:881-7.
6. Slaughter MS, Pagani FD, Rogers JG, Miller LW, Sun B, Russell SD et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant 2010;29(4 Suppl):S1-39.
7. Snyder TA, Watach MJ, Litwak KN, Wagner WR. Platelet activation, aggregation, and life span in calves implanted with axial flow ventricular assist devices. Ann Thorac Surg 2002;73:1933-8.
8. Eckman PM, John R. Bleeding and thrombosis in patients with continuousflow ventricular assist devices. Circulation 2012;125:3038-47.
9. John R, Panch S, Hrabe J, Wei P, Solovey A, Joyce L et al. Activation of endothelial and coagulation systems in left ventricular assist device recipients. Ann Thorac Surg 2009;88:1171-9.
10. Majeed F, Kop WJ, Poston RS, Kallam S, Mehra MR. Prospective, observational study of antiplatelet and coagulation biomarkers as predictors of thromboembolic events after implantation of ventricular assist devices. Nat Clin Pract Cardiovasc Med 2009;6:147-57.
11. Reikvam H, Steien E, Hauge B, Liseth K, Hagen KG, Størkson R et al. Thrombelastography. Transfus Apher Sci 2009;40:119-23.
12. Interagency registry for mechanically assisted circulatory support manual of operations version 2.3 (published 30 October 2008). http://www.uab.edu/ ctsresearch/intermacs/manuals.htm (30 August 2012, date last accessed).
13. Slaughter MS, Naka Y, John R, Boyle A, Conte JV, Russell SD et al. Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. J Heart Lung Transplant 2010;29:616-24.
14. Uriel N, Pak SW, Jorde UP, Jude B, Susen S, Vincentelli A et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 2010;56: 1207-13.
15. Kushnir VM, Sharma S, Ewald GA, Seccombe J, Novak E, Wang IW et al. Evaluation of GI bleeding after implantation of left ventricular assist device. Gastrointest Endosc 2012;75:973-9.
16. Menon AK, Götzenich A, Sassmannshausen H, Haushofer M, Autschbach R, Spillner JW. Low stroke rate and few thromboembolic events after HeartMate II implantation under mild anticoagulation. Eur J Cardiothorac Surg 2012;42:319-23; discussion 323.
17. Demirozu ZT, Radovancevic R, Hochman LF, Gregoric ID, Letsou GV, Kar B et al. Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. J Heart Lung Transplant 2011;30:849-53.